New Drug Approvals in 2024: How Did The Industry Fare?
By

By
How did the industry fare with new drug approvals in 2023? What new drugs were approved by FDA and were approvals in pace with prior years? What was the mix between small molecules and biologics, and which companies and products made the mark? DCAT Value Chain Insights sums it up.

Have Your Company be A Newsmaker at DCAT Week
By

By
Applications are closing Wednesday February 5 for the DCAT Member Company Announcement Forum, a much-anticipated event at DCAT Week in which senior executives from DCAT Member Companies highlight major news announcements covering expansions, M&A, and other key strategic developments.

Industry Roundtable: Small-Molecule APIs
By

By
What are the key issues shaping the market for small-molecule drugs and related trends in manufacturing? An industry roundtable of senior executives share their perspectives on what is driving the market.

What Trending: Biologic-Based Drugs
By

By
What were the biologic-based drugs approved by FDA’s Center for Drug Evaluation and Research in 2024? Which companies and products crossed the regulatory finish line and how do they fit in the market?

Upcoming DCAT European Conference: Expedition Pharma: Innovation from a Patient-First Perspective   
By

By
How is innovation inspiring and fueling the transformation of the bio/pharma industry?DCAT’s conference and networking event, Expedition Pharma: Innovation from a Patient-First Perspective, being held June 4–5, 2025, in Lugano, Switzerland, will provide key insights.  

The Bio/Pharma Majors’ Strategies & Products: Where Do Small-Molecule Drugs Rank?
By

By
How do small-molecule drugs rank in the strategy of the bio/pharmaceutical majors? What are the leading products from a revenue perspective, and what are key developments on a commercial and pipeline basis? DCAT Value Chain Insights looks at what may in store for 2025.

CDMO/CMO Outlook: What May Be in Store for 2025
By

By
What are key issues shaping the market for bio/pharmaceutical outsourcing in the coming year? DCAT Value Chain Insights takes an inside look into the market drivers, trends, and key activity shaping the CDMO/CMO market.

Will the ADC Wave Continue in 2025?
By

By
Deal-making by the large pharma companies in antibody drug conjugates (ADCs) to build their in product portfolios in oncology has been on the upsurge, but will the ADC wave continue in 2025? A look at recent deals and what may lie ahead.

Bio/Pharma Outlook 2025: The Year Ahead
By

By
What are the key issues on the bio/pharma industry’s radar in 2025? DCAT Value Chain Insights weighs in on the key trends and developments shaping the industry in the year ahead: from manufacturing and supply lines to product innovation and new drug development.

Partnering for Innovation in Manufacturing & Supply
By

By
How are bio/pharma companies and their partners collaborating to resolve the difficult challenges that arise in development, manufacturing, and the supply chain? DCAT Member Companies are invited to apply to share fresh insights, best practices, and lessons learned at a DCAT Week program. Applications close January 13, 2025.